AEON
AEON Biopharma, Inc. [AEON] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AEON Stock Summary
Top 10 Correlated ETFs
AEON
Top 10 Correlated Stocks
AEON
In the News
AEON Financial details
Company Rating
-
Market Cap
289.71M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
05 Jul 2024
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-7.35
Quick Ratio
0.12
Current Ratio
0.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
67.35%
SMA50
32.26%
SMA100
-92.3%
Inst Own
-
Inst Trans
-
ROA
-488%
ROE
20%
ROC
0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.37-17.17
52W High
-94.64%
52W Low
-69.62%
RSI
66.99
Rel Volume
6.68
Avg Volume
58.37K
Volume
390.03K
Perf Week
39.13%
Perf Month
108.54%
Perf Quarter
-98.1%
Perf Half Y
-98.59%
-
-
-
-
Beta
0.412
-
-
Volatility
0.07%, 0.16%
Prev Close
2.16%
Price
0.9113
Change
-1.8%
Company Profile
- Volume Average 58.37K
- Market Capitalization 289.71M
- Employee 10
- CEO Mr. Marc Forth
- Headquarters Newport Beach,CA,US
- IPO Date 2023-07-24
-
Website
http://www.aeonbiopharma.com 
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
